论文部分内容阅读
本文报告运用喘息灵糖浆治疗急发期支气管哮喘98例的临床实验研究,并以组合西药治疗作为对照(98例)。结果:观察组控显率为69.3％,总有效率为89.7％,两组疗效无显著差异(P>0.05),但观察组毒副作用明显低于西药组(P<0.01)。研究结果提示,喘息灵具有调节T淋巴细胞亚群,提高细胞免疫机能及降低血清IgE水平的功效,7项免疫指标治疗前后差异显著(P<0.05),西药组治前后无显著差异(P>0.05)。喘息灵糖浆可作为治疗急发期支气管哮喘的有效制剂。
This article reports the use of astragalus syrup for the treatment of 98 cases of bronchial asthma clinical trials, and the combination of western medicine as a control (98 cases). Results: The observation group had a significant rate of 69.3% and a total effective rate of 89.7%. There was no significant difference between the two groups (P> 0.05). However, the side effects in the observation group were significantly lower than those in the western medicine group (P <0.01). The results of the study suggest that asthma spirit has the effects of regulating T lymphocyte subsets, improving cellular immune function and lowering serum IgE levels. There are significant differences between the seven immune indexes before and after treatment (P <0.05), but there is no significant difference between the western medicine group before and after treatment (P> 0.05). Astragalus syrup can be used as an effective treatment of bronchial asthma during acute phase preparation.